Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 36, Numéro 5, Mai 2020
|
|
|---|---|---|
| Page(s) | 437 - 439 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2020068 | |
| Publié en ligne | 26 mai 2020 | |
- IlieM, Long-MiraE, BenceC, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016 ; 27 : 147–153. [CrossRef] [PubMed] [Google Scholar]
- HellmannMD, Paz-AresL, Bernabe CaroR, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019 ; 381 : 2020–2031. [Google Scholar]
- ChenDS, MellmanI. Elements of cancer immunity and the cancer-immune set point. Nature 2017 ; 541 : 321–330. [Google Scholar]
- SkoulidisF, GoldbergME, GreenawaltDM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 2018 ; 8 : 822–835. [CrossRef] [PubMed] [Google Scholar]
- PengW, ChenJQ, LiuC, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016 ; 6 : 202–216. [CrossRef] [PubMed] [Google Scholar]
- KoyamaS, AkbayEA, LiYY, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res 2016 ; 76 : 999–1008. [Google Scholar]
- MazieresJ, DrilonA, LusqueA, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the Immunotarget registry. Ann Oncol 2019 ; 30 : 1321–1328. [CrossRef] [PubMed] [Google Scholar]
- GuibertN, JonesG, BeelerJF, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer Amst Neth 2019 ; 137 : 1–6. [CrossRef] [Google Scholar]
- RizviH, Sanchez-VegaF, LaK, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 2018 ; 36 : 633–641. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.